Soluble complement receptor 1: TCEL and SmithKline Beecham agreed to close the initial Phase I trial of sCR1 conducted by SmithKline in burn patients at risk of

The trial will be unblinded and data analyzed and used to provide initial safety and pharmacokinetic data in support of new clinical trials.

TCEL plans to initiate trials in a larger population of ARDS patients as well as broaden clinical evaluation of the product into a cardiovascular indication. Both of these trials will use sCR1 produced from a new manufacturing process developed by SmithKline. ...